Sign In
Buy OTLK
$0.81
-0.0038 (-0.467%)
At Close: Jun 03, 2026
Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
07:38am, Wednesday, 19'th Jun 2024
It's essential to remember that low-float biopharmaceutical companies often experience volatility due to frequent breaking news and technical factors such as float size and short interest. While the b
Outlook Therapeutics: Worth A Good Strong Look After CRL
05:22pm, Thursday, 13'th Jun 2024
Outlook Therapeutics received a Complete Response Letter from the FDA in August 2023, causing a 74% drop in share price. Following a Type A meeting with the FDA in November 2023, Outlook agreed to con
Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market
05:50am, Thursday, 13'th Jun 2024
Outlook Therapeutics is resubmitting a BLA for ONS-5010 by 2024, with top-line data expected in Q4, 2024. ONS-5010 received European Commission Marketing Authorization for treating wet AMD in May 2024
Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series
10:00am, Wednesday, 12'th Jun 2024
Live webcast on Thursday, June 13th at 4:00 PM ET FRENCHTOWN, NJ / ACCESSWIRE / June 12, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announc
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
09:05am, Tuesday, 11'th Jun 2024
ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevaciz
Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
10:30am, Thursday, 06'th Jun 2024
Watch the "What This Means" video here Outlook CEO, Russ Trenary underscores that LYTENAVA™ (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commiss
ISELIN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizu
Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript
02:35pm, Thursday, 16'th May 2024
Outlook Therapeutics, Inc. (NASDAQ:OTLK ) Q2 2024 Earnings Conference Call May 16, 2024 8:30 AM ET Company Participants Jenene Thomas - IR, JTC Team, LLC Russell Trenary - President & CEO Lawrence Ken
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
05:00pm, Wednesday, 15'th May 2024
ISELIN, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first authorized use of an ophthalm
ISELIN, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first authorized use of an ophthalm
ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab
Outlook Therapeutics® to Present at the Retina World Congress 2024
09:05am, Thursday, 02'nd May 2024
ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
09:00am, Monday, 29'th Apr 2024
ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizum
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
04:15pm, Monday, 15'th Apr 2024
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizum
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
12:54pm, Monday, 15'th Apr 2024
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise
